Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
National Institutes of Health Nationwide (Federal)
Deadline
2027-10-15
Region
Nationwide (Federal)
Funder type
Federal Government
For
Nonprofits & businesses
Sectors
Health & Human Services
About this program
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) — U.S. federal funding opportunity (PAR-25-184) from National Institutes of Health. See grants.gov for full eligibility and details.
Is this grant worth your time?
Create a free account and Happy Grants scores this program — and 2,000+ others — against your organization's profile in about a minute, with the reasons explained.
See your match score — freeRelated programs
Cartier Women's Initiative Awards
Cartier Women's Initiative
Applications open for Egypt Annual Program Statement (Egypt)
U.S. Department of State
2026-08-31RFAs: Unlocking Dataset Value for AI-Enabled Scientific Discovery (US)
U.S. National Science Foundation (NSF)
2026-11-04EcoConnexions From the Ground Up Program (US)
CN / America in Bloom
RollingRBC Foundation USA Community Investments
RBC Foundation USA
up to US$2,500,000 RollingPathfinder Grant (Exploration Fund Grant)
Explorers Club
US$2,500 to US$5,000 2026-08-31